imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
fluconazol "accord" 150 mg kapsler, hårde
accord healthcare b.v. - fluconazol - kapsler, hårde - 150 mg
fluconazol "accord" 200 mg kapsler, hårde
accord healthcare b.v. - fluconazol - kapsler, hårde - 200 mg
fluconazol "hexal" 100 mg kapsler, hårde
hexal a/s - fluconazol - kapsler, hårde - 100 mg
fluconazol "hexal" 150 mg kapsler, hårde
hexal a/s - fluconazol - kapsler, hårde - 150 mg
fluconazol "hexal" 200 mg kapsler, hårde
hexal a/s - fluconazol - kapsler, hårde - 200 mg
fluconazol "krka" 150 mg kapsler, hårde
krka sverige ab - fluconazol - kapsler, hårde - 150 mg
fluconazol "krka" 200 mg kapsler, hårde
krka sverige ab - fluconazol - kapsler, hårde - 200 mg
voriconazole "sandoz" 200 mg filmovertrukne tabletter
sandoz a/s - voriconazol - filmovertrukne tabletter - 200 mg
lopinavir/ritonavir mylan
mylan pharmaceuticals limited - lopinavir, ritonavir - hiv infektioner - antivirale midler til systemisk anvendelse - lopinavir/ritonavir angives i kombination med andre antiretrovirale lægemidler til behandling af human immundefekt virus (hiv-1) inficeret voksne, unge og børn over 2 år. valget af lopinavir/ritonavir til at behandle proteasehæmmer oplevet hiv-1-inficerede patienter bør være baseret på individuelle viral resistens test og historie behandling af patienter.